可药性
转录因子
生物
表观遗传学
癌变
抄写(语言学)
癌症研究
转移
计算生物学
癌症
基因
遗传学
生物信息学
语言学
哲学
出处
期刊:Springer US eBooks
[Springer Nature]
日期:2022-10-21
卷期号:: 107-131
标识
DOI:10.1007/978-1-0716-2815-7_9
摘要
AbstractDeregulation of transcription factors is critical to hallmarks of cancer. Genetic mutations, gene fusions, amplifications or deletions, epigenetic alternations, and aberrant post-transcriptional modification of transcription factors are involved in the regulation of various stages of carcinogenesis, including cancer initiation, progression, and metastasis. Thus, targeting the dysfunctional transcription factors may lead to new cancer therapeutic strategies. However, transcription factors are conventionally considered as “undruggable.” Here, we summarize the recent progresses in understanding the regulation of transcription factors in cancers and strategies to target transcription factors and co-factors for preclinical and clinical drug development, particularly focusing on c-Myc, YAP/TAZ, and β-catenin due to their significance and interplays in cancer.Key wordsTranscription factorTranscription co-factorsCancerUndruggableDruggable
科研通智能强力驱动
Strongly Powered by AbleSci AI